Compare TG Therapeutics Inc (TGTX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs TotalEnergies SE — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while TotalEnergies SE trades at $91.46 (market cap $200.03B). The key difference: TotalEnergies SE is far larger — about 23.5× TG Therapeutics Inc's market cap, and TotalEnergies SE pays a 4.7% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TTE | |
|---|---|---|
Market Cap | $8.53B | $200.03B |
Sector | Health | Energy |
52-Week High | $59.06 | $93.60 |
52-Week Low | $26.94 | $57.39 |
Enterprise Value | $8.74B | $231.02B |
Dividend Yield | — | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
TotalEnergies (TTE) trades at $90.1, up 1.7% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $98. Recent earnings show a beat in Q2 2026, and the company is advancing key LNG projects in Papua New Guinea and Angola. Cash flow improved to a positive $358 million in 2025, though revenue has declined from 2022 peaks.
The outlook is positive given analyst support and strategic investments, but risks include volatile oil prices and execution challenges. The stock offers value with a P/E of 11.28 and a 9.08% net margin, supported by a strong dividend history. Investors should weigh growth initiatives against energy market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
